GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (FRA:M55) » Definitions » Cash Payments

Macrogenics (FRA:M55) Cash Payments


View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.


Macrogenics Business Description

Traded in Other Exchanges
Address
9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).